Lifecycle
Announced
stage pending
Spin-off detail
ABVC BIOPHARMA, INC. -> SpinCo
ABVC / n/a ยท detected 2026-03-05
Triage
Reject
REJECT_JUNK
Confidence
35%
detection/extraction
Listing
n/a
distribution n/a
Extracted thesis
Board ”) until the next annual shareholders meeting and until their successors are duly elected and qualified;
Any shareholder giving a Proxy may revoke it prior to the time it is voted by notifying the Secretary, in writing, to that effect, by filing with him/her a later dated Proxy.
If you are a registered shareholder, please vote your shares as soon as possible by completing, signing, dating, and returning the enclosed proxy card in the postage-paid envelope provided.
I want to thank all of our shareholders as we look forward to what we believe will be an exciting future for our business.
This notice and the enclosed proxy statement are first being mailed to Shareholders on or about March 5, 2026.
Important Notice Regarding the Availability of Proxy Materials for the Annual Shareholder Meeting to Be Held at 10:00 a.m.
Risk flags
Operational dependency flags: transitional_services, related_party_agreements.
risk
Estimated float is unavailable from current filing data.
risk
Source Links
3-Year Financials
Revenue by year
Operating income or ebit by year
Margin by year
Margin trend
Ownership and float
Total shares
Parent retained shares percent
Insider or management shares percent
Restricted or locked up shares
Estimated float percent
Assumption noteFloat estimate unavailable from filing text.
Management incentives
Management ownership percent
Equity comp alignment indicators["20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No."]
Parent to spinoff leadership migration